Galectin-9在PD-1/PD-L1抑制剂联合化疗非小细胞肺癌患者免疫微环境中的作用  

The effects of Galectin-9 in the immune microenvironment of non-small cell lung cancer PD-1/PD-L1 inhibitor combined with chemotherapy

作　　者：廉政君[1] 叶红伟 石学萍[2] 米热古丽·阿不都热合曼 LIAN Zhengjun;YE Hongwei;SHI Xueping(Department of Oncology,The Eighth Affiliated Hospital of Xinjiang Medical University,Xinjiang,Urumqi 830000,China;不详)

机构地区：[1]新疆医科大学第八附属医院肿瘤内科,乌鲁木齐市830000 [2]新疆医科大学第八附属医院病理科,乌鲁木齐市830000

出　　处：《河北医药》2022年第21期3221-3224,3229,共5页Hebei Medical Journal

基　　金：新疆维吾尔自治区新疆医科大学第八附属医院院内课题(编号:2020008)。

摘　　要：目的探讨半乳凝集素-9(Galectin-9)在非小细胞肺癌(NSCLC)程序性细胞死亡受体-1(PD-1)/程序性细胞死亡受体配体-1(PD-L1)抑制剂联合化疗免疫微环境中的作用。方法选取2019年5月至2021年3月收治的NSCLC患者30例,取活检组织标本,检测Galectin-9、PD-1、PD-L1、T细胞免疫球蛋白黏蛋白3(Tim3)、淋巴细胞活化基因3(LAG3)表达水平,测定血清CD_(4)^(+)、CD_(8)^(+)表达水平,分析Galectin-9与PD-1、PD-L1、TIM3、LAG3及CD_(4)^(+)、CD_(8)^(+)水平的相关性,对比不同疗效患者治疗前后上述指标表达水平,Logistic回归分析疗效影响因素。结果Galectin-9高表达组Ⅳ期、淋巴结转移比例及PD-1、PD-L1、TIM3、LAG3、CD_(8)^(+)表达水平高于低表达组,CD_(4)^(+)表达水平低于低表达组(P<0.05);Galectin-9与PD-1、PD-L1、TIM3、LAG3、CD_(8)^(+)呈正相关(P<0.05),与CD_(4)^(+)呈负相关(P<0.05);疾病控制患者治疗后NSCLC组织Galectin-9、PD-1、PD-L1、TIM3、LAG3及血清CD_(8)^(+)表达水平低于治疗前(P<0.05),血清CD_(4)^(+)表达水平高于治疗前(P<0.05);进展患者治疗前后NSCLC组织Galectin-9、PD-1、PD-L1、TIM3、LAG3及血清CD_(4)^(+)、CD_(8)^(+)表达水平比较,差异无统计学意义(P>0.05);Logistic回归分析显示,治疗前Galectin-9、PD-1、PD-L1、TIM3、LAG3、CD_(4)^(+)、CD_(8)^(+)均为疗效影响因素(P<0.05)。结论NSCLC患者肿瘤组织Galectin-9与免疫检查点PD-1、PD-L1、TIM3、LAG3及血清CD_(4)^(+)、CD_(8)^(+)表达水平相关,可作为NSCLC患者接受PD-1/PD-L1抑制剂治疗时免疫状态及疗效的监测指标。Objective To investigate the effects of Galectin-9(Galectin-9)in the immune microenvironment of non-small cell lung cancer(NSCLC)programmed cell death receptor-1(PD-1)/programmed cell death receptor ligand-1(PD-L1)inhibitor combined with chemotherapy.Methods Thirty patients with NSCLC who were treated in our hospital were enrolled in the study.The biopsy tissue samples were taken to detect the expression levels of Galectin-9,PD-1,PD-L1,T cell immunoglobulin molecule 3(Tim3),and lymphocyte activation gene 3(LAG3),and the serum levels of CD_(4)^(+)and CD_(8)^(+)were measured,and the correlation between Galectin-9 and PD-1,PD-L1,TIM3,LAG3 and CD_(4)^(+)and CD_(8)^(+)levels was analyzed.Moreover the above indexes before and after treatment in patients with different therapeutic effects were compared,and the factors affecting the therapeutic effects were analyzed by Logistic regression.Results The proportion of stageⅣand lymph node metastasis,and the expression levels of PD-1,PD-L1,TIM3,LAG3,CD_(8)^(+)in Galectin-9 high expression group were significantly higher than those in low expression group,however,the expression levels of CD_(4)^(+)were significantly lower than those in low expression group(P<0.05).And Galectin-9 was positively correlated with PD-1,PD-L1,TIM3,LAG3,and CD_(8)^(+),however,which was negatively correlated with CD_(4)^(+)(P<0.05).After treatment the expression levels of Galectin-9,PD-1,PD-L1,TIM3,LAG3 and serum CD_(8)^(+)in NSCLC tissue of disease control patient were significantly lower than those before treatment,but,the serum levels of CD_(4)^(+)were significantly higher than those before treatment(P<0.05).There were no significant differences in the expression levels of Galectin-9,PD-1,PD-L1,TIM3,LAG3 and serum CD_(4)^(+)and CD_(8)^(+)in NSCLC tissues of advanced patients before and after treatment(P>0.05).Logistic regression analysis showed that Galectin-9,PD-1,PD-L1,TIM3,LAG3,CD_(4)^(+),and CD_(8)^(+)before treatment were factors affecting the curative effects(P<0.05).Conclusion Galectin-9 i

关 键 词：非小细胞肺癌 半乳凝集素-9 免疫检查点 程序性细胞死亡受体-1/程序性细胞死亡受体配体-1抑制剂 免疫微环境 

分 类 号：R743.2[医药卫生—神经病学与精神病学]